Global Colon Cancer Association to Host Webinar on HER2-Positive Colorectal Cancer and Biomarker Testing for Patient Advocates
核心洞察
The Global Colon Cancer Association (搜索) is hosting a free webinar on July 29, 2026, focused on HER2-positive colorectal cancer (搜索) and the role of biomarker testing in guiding care.
The event features John Strickler, MD, of Duke University, a leader in precision cancer medicine, alongside patient advocate and MOUNTAINEER trial participant Elle Charnisky.
Attendees will learn about HER2 (搜索) biology in colorectal cancer, the importance of biomarker testing, and how test results can identify clinical trial opportunities.
The Global Colon Cancer Association (搜索) (GCCA) will host a free educational webinar titled "HER2 (搜索) and Colorectal Cancer: What Advocates Need to Know" on Wednesday, July 29, 2026, at 11:00 AM EDT (3:00 PM UTC). The event is designed to equip patient advocates with practical knowledge about HER2-positive colorectal cancer (搜索) and the critical role biomarker testing can play in guiding clinical care.
The webinar brings together leading expertise in precision oncology and the lived patient experience. John Strickler, MD, of Duke University — who serves as Co-Leader of the Precision Cancer Medicine and Investigational Therapeutics Program, Leader of the Molecular Tumor Board, and Associate Director of Clinical Research for GI Oncology — will provide the clinical and scientific perspective. He will be joined by Elle Charnisky, a colorectal cancer advocate and participant in the MOUNTAINEER clinical trial, who will share the patient perspective on navigating precision medicine. The session will be moderated by Nicole Sheahan, President of the Global Colon Cancer Association (搜索).
Educational Objectives and Key Topics
The webinar curriculum is structured around several core learning objectives. Attendees will gain an understanding of what HER2 (搜索) is and its specific role in colorectal cancer biology. The program will explain why biomarker testing matters in the management of colorectal cancer and how advocates can support patients in accessing biomarker testing. Additionally, the session will explore how biomarker results may help identify clinical trial opportunities, offering patients potential pathways to investigational therapies.
The Patient Voice in Precision Medicine
A distinctive feature of the webinar is the inclusion of Elle Charnisky's firsthand account as a participant in the MOUNTAINEER clinical trial. The MOUNTAINEER trial has been a pivotal study evaluating HER2 (搜索)-directed therapy in colorectal cancer, and Charnisky's perspective is expected to provide advocates with a deeper understanding of what patients experience when navigating biomarker-driven treatment decisions and clinical trial participation.
Support and Registration
The educational program is supported by Pfizer. The Global Colon Cancer Association (搜索) has made registration open to all interested advocates and healthcare stakeholders seeking to improve patient access to appropriate testing, treatment options, and clinical trials in HER2-positive colorectal cancer (搜索).